(Q37374236)

20 August 2017

0 references

1 reference

title

Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review (English)

1 reference

20 August 2017

main subject

arterial hypertension

0 references

1 reference

V M Musini

1

1 reference

20 August 2017

P M Fortin

series ordinal

2

1 reference

20 August 2017

K Bassett

series ordinal

3

1 reference

20 August 2017

J M Wright

series ordinal

4

1 reference

20 August 2017

publication date

22 January 2009

1 reference

Journal of Human Hypertension

20 August 2017

published in

1 reference

20 August 2017

volume

23

1 reference

20 August 2017

issue

8

1 reference

20 August 2017

page(s)

495-502

1 reference

https://scigraph.springernature.com/pub.10.1038/jhh.2008.162

20 August 2017

exact match

0 references

cites work

Renin inhibition: a new approach to cardiovascular therapy

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.162

Studies on renin antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.162

7 January 2021

Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.162

7 January 2021

Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.162

7 January 2021

Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.162

7 January 2021

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.162

7 January 2021

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.162

7 January 2021

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.162

7 January 2021

Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.162

7 January 2021

Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.162

7 January 2021

Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.162

7 January 2021

Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.162

7 January 2021

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2008.162

7 January 2021

Identifiers

DOI

10.1038/JHH.2008.162

1 reference

20 August 2017

1 reference